close_menu
Latest News

Health

Collaborative institute aims to speed cancer drug creation

WASHINGTON (AP) -- House Republicans on Wednesday abruptly canceled a committee vote on a plan to help Puerto Rico deal with its $70 billion debt in the face of conservative opposition.

A vote on the bill establishing a control board had been scheduled for Thursday with a sense of urgency, as Puerto Rico faces a deadline for a multimillion-dollar bond payment next month. The government has said it will likely default, which would mark the first time Puerto Rico would default on general obligation bonds protected by the island's constitution.

A spokeswoman for the House Natural Resources Committee said Thursday's meeting has been canceled and has not yet been rescheduled.

Committee Chairman Rob Bishop, R-Utah, said there was still uncertainty in both parties and the administration was still pushing for changes.

"It is unfair to all members to force a vote with provisions still being negotiated," Bishop said in a statement.

Obama administration officials warned at a hearing Wednesday that the island is facing total financial collapse if Congress doesn't step in. Gov. Alejandro Garcia Padilla has warned that a debt restructuring measure needs to be approved soon as the deadline for a $422 million bond payment looms in May.

Republicans agree on the urgency of the matter, but have faced opposition from within their own caucus and from Democrats.

Legislation released by the panel this week would create a control board and allow the board to facilitate some court-ordered debt restructuring, though it does not give the island the broad bankruptcy authority that territorial officials had sought.

Democrats worried that the control board would be too powerful, prompting echoes of colonialism.

Some conservative Republicans had objected to the debt restructuring, saying it's a bad precedent. In an attempt to satisfy those lawmakers, the most recent draft of the bill would give creditors more of a say on debt plans, allowing them a preliminary vote on whether they wanted to voluntarily restructure debt.

But it was not enough. At Wednesday's hearing, several Republicans on the panel expressed concern about the debt restructuring, making the outcome of Thursday's committee vote unclear.

"I believe we're going down a slippery slope here," said Rep. Jeff Duncan, R-S.C.

Rep. John Fleming, R-La., also opposed the bill, and said Bishop had tried to encourage members to easily pass it in committee or leave the room when the vote occurred.

"To be asked to walk away -- to be told to miss a vote -- is a request that flies in the face of every member's conscience. Leadership had no business making such a request," said Fleming, who vowed to defeat the legislation.

Parish Braden, a spokesman for Bishop, confirmed the congressman had requested a voice vote, which is not recorded. But Bishop said it was fine if members wanted a recorded vote, Braden said.

The House Republican Study Committee, a group of around 170 conservatives, had expressed concerns about the debt restructuring provisions. Texas Rep. Bill Flores, the group's leader, said members were encouraged by a new draft this week made some concessions to the island's creditors, but the group still had not endorsed the bill.

At the hearing, Treasury Department official Antonio Weiss said prompt action was needed because Puerto Rico is in distress. But he said the administration is concerned that allowing creditors to vote on debt restructuring could delay the process.

Later Wednesday, White House Press Secretary Josh Earnest said the administration is confident a solution can be reached, but added that the creditors "are almost by definition rich and powerful people who have a clear financial interest in getting a deal that reflects their financial interest and not the interest of the 3.5 million people living in Puerto Rico."

Earnest added, "Overcoming that dynamic is something that will be challenging for Congress to do."

The newest version of the bill would increase the size of the control board from five to seven seats, with the two added members picked by the minority party in the House and Senate -- a clear enticement to Democrats who have opposed the bill. House Democratic leader Nancy Pelosi of California said still more work needs to be done "to improve the makeup and scope of the board."

Speaker Paul Ryan, R-Wis., endorsed the legislation and tried to encourage his colleagues to sign on.

"Congress has a constitutional and financial responsibility to bring order to the chaos that is unfolding in the U.S. territory -- chaos that could soon wreak havoc on the American bond market," Ryan said.

Puerto Rico has been mired in economic stagnation for a decade. The financial problems worsened as a result of setbacks in the wider U.S. economy, and government spending in Puerto Rico continued unchecked as borrowing covered increasing deficits.

Puerto Rico Senate President Eduardo Bhatia noted that it is running out of time to address its fiscal crisis but insisted that the proposed bill was draconian.

"What happened in federal Congress today opens up a new panorama for Puerto Rico," he said. "The measure submitted requires profound amendments."

A revised bill should respect Puerto Rico's democracy and help promote economic development, among other things, he said.

A spokeswoman for Gov. Alejandro Garcia Padilla did not immediately return a request for comment.

___

Associated Press writer Danica Coto in San Juan, Puerto Rico, contributed to this report.

___

Follow Mary Clare Jalonick on Twitter at http://twitter.com/mcjalonick


Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
[gallery ids='256076,256075,256074,256073,256072,']

TRENTON, N.J. (AP) — A project to speed development of cancer-fighting drugs that harness the immune system has academic and drug industry researchers collaborating and sharing their findings like never before.

The newly created Parker Institute for Cancer Immunotherapy is being funded by a $250 million grant from Sean Parker, the co-founder of the file-sharing site Napster and Facebook’s first president. It brings together partners at six top academic cancer centers, dozens of drugmakers and other groups.

“Everybody knows that we need to move forward and change the model” for cancer research, Jeffrey Bluestone, an immunology researcher and the institute’s CEO, told The Associated Press Tuesday. “The goal here is to rapidly move our discoveries to patients.”

For decades, fiercely competitive and secretive drugmakers protected their money-making discoveries with patents and lawsuits. Academic researchers likewise often guarded their work closely until it was published because their promotions, awards and sometimes revenue from licensing patents depended on individual achievement. That often slowed progress.

With the increasing cost and complexity of research, drugmakers began licensing or buying patents and research programs from university researchers. Then big drugmakers began collaborating with each other and buying smaller companies, to share research costs, speed up the drug development process and get an edge on rivals.

The Parker Institute, founded nine months ago, pushes those trends to a new level, by creating a virtual “sandbox” in which scientists at different institutions can work collaboratively, Bluestone said.

About 300 scientists at leading cancer institutions — Memorial Sloan Kettering Cancer Center; Stanford Medicine; University of California, Los Angeles; University of California, San Francisco; University of Pennsylvania; and The University of Texas MD Anderson Cancer Center — will share their findings.

They’ll focus on early research. After initial patient testing, the institute’s technology-transfer committee will strike licensing deals with drugmakers best able to develop those drugs, providing funding for other early research. Those drugmakers, from industry giants Amgen Inc. and Pfizer Inc., to small drug and diagnostic test developers, will fund the much-larger tests needed for drug approval, which can include hundreds or thousands of patients and cost hundreds of millions of dollars.

Parker worked with hundreds of scientists to create a roadmap for the institute’s work. It will quickly fund projects fitting its scientific targets and then rapidly enroll many of the 300,000 or more patients treated at the six centers each year in tests of resulting experimental drugs.

“We’ll make progress against three or four cancer types in the next several years,” Parker predicts.

He added that to be most effective, immunotherapy must become an initial treatment. Now it’s usually reserved until patients relapse after chemotherapy and other standard treatments that weaken the immune system.

Scientists have tried less-sophisticated strategies to use the immune system against cancer for about a century, with limited success, noted Dr. Eric Rubin, head of early stage cancer drug development at Merck & Co. It took recent advances in cell biology, genetics and related science to make progress. Now there are a handful of approved immunotherapy drugs that greatly extend lives of some patients with lung cancer and melanoma.

Those include Merck’s Keytruda and Bristol-Myers Squibb Co.’s Yervoy and Opdivo. They are so-called “checkpoint inhibitors,” which block molecules that slow down or turn off the immune system’s ability to attack cancer cells.

Other immunotherapy approaches that will be part of the institute’s initial work include CAR-T therapy, in which a patient’s T-cells are removed from the blood, engineered to be “cancer assassins,” then injected into the patient, Parker said. Researchers also will develop therapeutic viruses and vaccines to drive the immune system to recognize and attack tumors.

“The Parker Institute does have the potential to accelerate development (of drugs) that will enable a greater number of cures,” Rubin said. “We’re very happy to be part of this.”

___

Follow Linda A. Johnson at www.twitter.com/LindaJ_onPharm

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Comments

comments powered by Disqus
close_menu
Latest News